However, GIP was not successfully used for diabetes treatment, whereas Glucagon‐like peptide 1 (GLP‐1), the other incretin that was later characterized, was in line with a drug for diabetes, so‐called a GLP‐1 receptor agonist. Here, GLP1R is linked to diabetes mellitus.